Astellas Pharma Inc. ALPMY
16.90 USD -0.05 (-0.29%)
As ofNov 17, 2026, 3:59 PM EST
16.52 Day range 17.05
12.12 52-week range 17.35
- YTD
- +27.16%
- 1 year
- +39.21%
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
3.63 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
8 / 9 Strong
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
A+4 / 5 overall
- DCF 5
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 3
- P/B 3
Valuation
P/E 14.9×
P/S 2.0×
P/B 2.5×
P/FCF 8.6×
EV/EBITDA 7.2×
EV/Sales 2.0×
FCF Yield 11.7%
Profitability
Gross Margin 74.6%
Operating Margin 19.6%
Net Margin 13.6%
ROE 16.8%
ROIC 13.2%
ROA 8.6%
Growth (YoY)
Revenue 18.6%
Operating Income 984.4%
EPS (diluted) 511.0%
Free Cash Flow 293.1%
Financial Health
Current Ratio 1.2×
Quick Ratio 0.9×
Debt / Equity 0.1×
Net Debt / EBITDA -0.1×
Interest Coverage 29.8×
Dividends
Dividend Yield 3.1%
Payout Ratio 46.7%
Annual · latest fiscal year ends 2026-03-31
